Menopausal Hormone Therapy and Primary Prevention
Authors: Teresa M. Schaer
Journal: Annals of Internal Medicine (2013)

Letters15 January 2013Menopausal Hormone Therapy and Primary PreventionTeresa M. Schaer, MDTeresa M. Schaer, MDFrom UMDNJ–Robert Wood Johnson Medical School, New Brunswick, New Jersey.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-158-2-201301150-00021 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:In reading Nelson and colleagues' review on menopausal hormone therapy (1), I was concerned to find that this “systematic review” was far from comprehensive. In particular, it did not include the many studies that show how the human, nonpharmacologically altered form of progesterone—sometimes referred to as “natural” or “bioidentical” progesterone—is beneficial for the treatment and prevention of many chronic conditions, including such neurologic disorders as dementia and stroke (2), cardiovascular disease, and osteoporosis (3), in addition to breast cancer (4, 5).Progestin, the pharmacologically altered form of progesterone, has been associated with many negative health effects, as ...References1. Nelson HD, Walker M, Zakher B, Mitchell J. Menopausal hormone therapy for the primary prevention of chronic conditions: a systematic review to update the U.S. Preventive Services Task Force recommendations. Ann Intern Med. 2012;157:104-13. [PMID: 22786830] LinkGoogle Scholar2. Brinton RD, Thompson RF, Foy MR, Baudry M, Wang J, Finch CE, et al. Progesterone receptors: form and function in brain. Front Neuroendocrinol. 2008;29:313-39. [PMID: 18374402] CrossrefMedlineGoogle Scholar3. Seifert-Klauss V, Prior JC. Progesterone and bone: actions promoting bone health in women. J Osteoporos. 2010;2010:845180. [PMID: 21052538] CrossrefMedlineGoogle Scholar4. Campagnoli C, Clavel-Chapelon F, Kaaks R, Peris C, Berrino F. Progestins and progesterone in hormone replacement therapy and the risk of breast cancer. J Steroid Biochem Mol Biol. 2005;96:95-108. [PMID: 15908197] CrossrefMedlineGoogle Scholar5. Fournier A, Berrino F, Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res Treat. 2008;107:103-11. [PMID: 17333341] CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: From UMDNJ–Robert Wood Johnson Medical School, New Brunswick, New Jersey.Disclosures: None disclosed. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoMenopausal Hormone Therapy for the Primary Prevention of Chronic Conditions: A Systematic Review to Update the U.S. Preventive Services Task Force Recommendations Heidi D. Nelson , Miranda Walker , Bernadette Zakher , and Jennifer Mitchell Menopausal Hormone Therapy and Primary Prevention Heidi D. Nelson Metrics 15 January 2013Volume 158, Issue 2Page: 140-141KeywordsBreast cancerEstrogensHormonal therapyHormone replacement therapyHormonesMyocardial infarctionOsteoporosisProgesteroneProspective studiesSystematic reviews ePublished: 15 January 2013 Issue Published: 15 January 2013 CopyrightCopyright © 2013 by American College of Physicians. All Rights Reserved.PDF DownloadLoading ...